NEPENTHE

Analgesics

Rigshospitalet, DenmarkSmall moleculePhase 4 / ApprovedDormant

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 95/ 100

Competitive context

7 Active assets in the Analgesics cohort.

Asset / Sponsor	Phase	Rating
S-Ketamine Rigshospitalet, Denmark	Phase 4	BB
SUFENTANYL Rigshospitalet, Denmark	Phase 4	BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Evangelismos Hospital	Phase 4	BB
Zofran Rigshospitalet, Denmark	Phase 4	BB
HYDROMORPHON	Phase 3	B

View all 15 →

Same molecule, other indications

NEPENTHE is also rated in:

PainDormant

BBB

Indicative ·

77 / 100

cancer of unknown primary siteDormant

BBB

Indicative ·

75 / 100

chronic pain syndromeDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.